Sugar could be sweet solution to respiratory disease

Restriction or inhalation of common sugar could one day treat a range of respiratory diseases, according to new research led by University of Manchester biologists. The study in mice reveals how the ability of cells to use glucose helps to regulate the immune system during lung inflammation.

Their research suggests that blocking sugar receptors in the lung could reduce inflammation in chronic conditions such as asthma, allergies and parasitic worm infections.

On the other hand, the immune response against some infections could be enhanced by inhalation of sugar solutions.

The international study by scientists from The University of Manchester, AstraZeneca, The University of Southampton and the National Institute of Health in the United States is published in Nature Immunology today.

The study was funded by a range of bodies including the Wellcome Trust, Medical Research Council, BBSRC, AstraZeneca, Asthma UK and National Institute of Health.

Lead researcher Professor Andrew MacDonald from The University of Manchester, said: "Respiratory illnesses cause terrible suffering in both the developing and developed world.

"Hundreds of people are admitted to hospital every day in the UK with asthma attacks, while potentially deadly parasitic infections in the lungs are endemic across much of Africa and Asia.

"The idea that modifying glucose levels in the lungs could one day be a critical factor in treatment of these conditions is tremendously exciting."

The study looked at specialised white blood cells called macrophages- which have an important role in our bodies.

They act as the vacuum cleaners of the immune system - detecting and removing pathogenic organisms and debris.

But the team discovered that macrophages in the lungs need the correct levels of an energy source - glucose- for them to be able to function properly.

Using a special protein called interleukin 4 - typically found during inflammation caused by asthma or parasitic worm infection, and able to signal to other cells in the immune system - they tested the relationship between macrophages and glucose in mice.

Unexpectedly, macrophages in the lungs of mice treated with interleukin 4 did not respond normally.

And that poor response was associated with failure of the cells to be able to take up or use glucose.

Professor MacDonald added: "During inflammation of the type seen in asthma and parasitic worm infection it appears that glucose, and use of glucose, controls macrophage activation in the lungs.

"Clearly we now need to study the impact of glucose on human lung macrophages.

"As it's known that many cells in the lung have glucose receptors, we think future drug development is a possibility. However, attempting to treat aggressive inflammation by blocking glucose would be a balancing act, as all living things clearly need glucose as an overall energy source.

"On the flip side, it is possible that provision of glucose could increase inflammation to help protect against some lung infections. It's reasonable to suggest that short term inhalation therapy might one day work as such a treatment."

Freya R Svedberg, Sheila L Brown, Maria Z Krauss, Laura Campbell, Catherine Sharpe, Maryam Clausen, Gareth J Howell, Howard Clark, Jens Madsen, Christopher M Evans, Tara E Sutherland, Alasdair C Ivens, David J Thornton, Richard K Grencis, Tracy Hussell, Danen M Cunoosamy, Peter C Cook, Andrew S MacDonald.
The lung environment controls alveolar macrophage metabolism and responsiveness in type 2 inflammation.
Nature Immunology (2019). doi: 10.1038/s41590-019-0352-y.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...